Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP65: The association of fecal calprotectin level and combined mucosal and transmural healing in patients with Crohn's disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Soomin Noh
Created: Tuesday, 28 May 2019, 3:32 PM
Calprotectin and other faecal biomarkers, Crohn’s disease
Files: 1
DOP66: Surveillance colonoscopies in Ulcerative Colitis: Does it make a difference?
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Narula Neeraj
Created: Tuesday, 28 May 2019, 3:32 PM
Colonoscopic surveillance, colonoscopy, Colonoscopy, UC colorectal cancer surveillance, IBD-associated cancer, Colorectal cancer
Files: 1
DOP67: CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signaling pathway
Year: 2020
Source: ECCO'20 Vienna
Authors: Jieun Shin
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with inflammatory bowel disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Entcho Klenske
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Ulcerative colitis, colonoscopy, Mucosal healing, Chromoendoscopy, Colonoscopy, Mucosal healing, Disease activity indices, Mucosal healing
Files: 1
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
Year: 2020
Source: ECCO'20 Vienna
Authors: Desmond Chee
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Bram Verstockt
Created: Tuesday, 28 May 2019, 3:32 PM
Treat to target, Ustekinumab
Files: 1
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Peter Hasselblatt
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in ulcerative colitis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Katherine Li
Created: Tuesday, 28 May 2019, 3:32 PM
Histology, Ulcerative colitis, Mucosal healing, Ustekinumab, Mucosal healing, Mucosal healing
Files: 1
DOP71: Efficacy, safety, and tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn’s Disease: Results from, UniStar, a phase 1 study
Year: 2020
Source: ECCO'20 Vienna
Authors: Joel Rosh
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Michiel de Jong
Created: Tuesday, 28 May 2019, 3:32 PM
Crohn’s disease, Ulcerative colitis, Dysplasia, Dysplasia, Colorectal cancer
Files: 1
DOP72: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of Ulcerative Colitis: The open-label, multicentre, Phase 2a TUSCANY study
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP73: Efficacy and safety of escalation to tofacitinib 10mg BID for patients with UC following loss of response on 5mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
Year: 2020
Source: ECCO'20 Vienna
Authors: Alessandro Armuzzi
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Karin Wasmann
Created: Tuesday, 28 May 2019, 3:32 PM
Disease activity Indices, Patient reported outcomes, Quality of life (IBDQ), MDT, 5-ASA, Adalimumab, Anti-TNF agents, Infliximab, Thiopurines (AZA / MP), Perianal disease, Perianal fistulae, Abscess, Perianal disease, Adherence to therapy, Sexuality, Real world data, Patient reported outcomes
Files: 1
DOP74: Effectiveness of dose escalation in Crohn’s Disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy - A multicenter international cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Uri Kopylov
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multicenter observational study.
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Constance Biron
Created: Tuesday, 28 May 2019, 3:32 PM
Ustekinumab, Perianal fistulae, Perianal disease
Files: 1
DOP75: Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
Year: 2020
Source: ECCO'20 Vienna
Authors: Julián Panés
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP76: Corticosteroid sparing effects of ustekinumab therapy for Ulcerative Colitis through 2 years: UNIFI long-term extension
Year: 2020
Source: ECCO'20 Vienna
Authors: Laurent Peyrin-Biroulet
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s disease in a nationwide cohort
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Niels Qvist
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Crohn’s disease, Health economic analysis, Perianal disease
Files: 1
DOP77: Ustekinumab is associated with better effectiveness outcomes when compared to vedolizumab in Crohn's Disease patients with prior anti-TNF failure: Comparative effectiveness study from the ICC Registry
Year: 2020
Source: ECCO'20 Vienna
Authors: Marieke Pierik
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multicenter observational study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Constance Biron
Created: Tuesday, 28 May 2019, 3:32 PM
Vedolizumab, Perianal disease, Perianal disease
Files: 1